News
Cimeio Therapeutics Presents Additional Proof-of-Concept Data for SCIP Platform
Poster session at ASGCT meeting describes key progress with shielded CD45 cells.
Cimeio Therapeutics Presents SCIP Platform Proof-of-Concept Data at ASH
Preclinical data for Cimeio’s CD117- and CD123-shielded cells, and CD117 mAbs, demonstrate the potential of Cimeio’s SCIP platform to enable novel immunotherapy-based conditioning and post-transplant treatment approaches.
Cimeio Therapeutics Announces Issuance of Key Patent Covering Cell Therapy Platform
Cimeio Therapeutics today announced the U.S. Patent Office has issued a key patent covering the company’s Shielded-Cell & Immunotherapy Pairs (SCIP) platform.
Cimeio Therapeutics Announces Acceptance of ASH Abstracts Detailing Pipeline
Versant Ventures announced the debut of Cimeio Therapeutics, a biotechnology company developing a novel approach to cell therapies.
Versant Ventures Launches Cimeio Therapeutics with $50 Million Series A
Versant Ventures announced the debut of Cimeio Therapeutics, a biotechnology company developing a novel approach to cell therapies.